Treats relapsing forms of multiple sclerosis (MS). ANDA 207985, held by Glenmark Pharms Ltd. Fingolimod Hydrochloride.
As of Nov 16, 2026, ANDA 207985 (Fingolimod Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on Jun 18, 2020, with 3 approved supplements and 0 published complete response letters.
Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 18, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fingolimod HydrochlorideEQ 0.5MG BASE · capsule;oral | Fingolimod Hydrochloride | Rx |
| Jan 16, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 22, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 22, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 18, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters